Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript February 12, 2026 Vertex Pharmaceuticals ...

The most significant advancement in Gemini 3.1 Pro lies in its performance on rigorous logic benchmarks. Most notably, the model achieved a verified score of 77.1% on ARC-AGI-2.

Google launches Gemini 3.1 Pro with major gains in complex reasoning, multimodal capabilities, and benchmark-leading AI ...

The company has several juicy growth opportunities ahead of it, a market professional tracking its fortunes believes.

Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for this VRTX earnings update.

Vertex, Inc. is rated a Buy due to steady growth, margin expansion, recurring revenue, and high retention. Learn more about ...

Vertex Pharmaceuticals (VRTX 0.22%) is a great example of a biotech success story. The company has developed strength in a specialty area and, thanks to that, has delivered a track record of revenue ...

Vertex Inc. reports fourth-quarter results Wednesday before the market opens, a closely watched release that will test whether the tax software provider can translate favorable industry tailwinds into ...

Gemini 3 Deepthink is built for complex reasoning and can take 10–20 minutes per query, helping you get clearer, ...

I have been closely observing the crypto industry for the past few years, and it appears that the current market downturn is beginning to rival the slump in 2022. During the 2022 fiasco, major crypto ...

Google Gemini Enterprise for Customer Experience challenges where intelligence lives in the CX stack—and who owns the ...

Vertex saw its shares drop after its third-quarter earnings report in November. The biotech is looking to expand its portfolio into pain management and renal therapies. 10 stocks we like better than ...